Dade Behring's Sales Rise in First Quarter
By Labmedica staff writers
Posted on 20 Apr 2001
For the first quarter of 2001, sales rose 13% over sales in the same period in 2000, reports Dade Behring (Deerfield, IL, USA). These results include a favorable one-time impact resulting from the company's adoption of a new accounting standard. Excluding this impact, sales were still up 7%. The growth was attributed to increased sales of the company's Dimension system and specialty product lines.Posted on 20 Apr 2001
For the full year 2000, however, revenues were US$1.184 billion, about a 10% decrease from 1999. Dade Behring says revenues were affected by rising interest rates and a falling Euro as well as a decision to insource the distribution of two important product lines, which required a significant short-term use of cash.
"We are continuing to take aggressive, well-considered steps to address our financial performance, which was disappointing in 2000,” said Jim Reid-Anderson, president and CEO. "Already, we have eliminated several layers of management, consolidated support areas, and completed a significant global restructuring. These actions are generating encouraging results, and we are seeing revenue and earnings growth versus both our current financial plan and prior year in the first quarter of 2001.”
Related Links:
Dade Behring
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
